Showing 421 - 440 results of 113,703 for search '(( i non decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.71s Refine Results
  1. 421
  2. 422
  3. 423

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  4. 424
  5. 425

    Image5_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…</p><p>Conclusion: PHLDA1 is a key regulator in the tumorigenesis and progression of Ewing sarcoma. …”
  6. 426

    Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination by Cheng Cheng (68821)

    Published 2012
    “…</p> <h3>Methods and Findings</h3><p>Ad seropositivity in the Step trial volunteers was analyzed using chimeric rAd5/35 vectors to characterize their specificity for Ad5 fiber and non-fiber external (capsid) proteins. …”
  7. 427
  8. 428
  9. 429
  10. 430
  11. 431
  12. 432
  13. 433
  14. 434

    Image1_Decreased mitochondrial respiration associates with frailty in community-dwelling older adults.jpg by Gianella Liabeuf (18512634)

    Published 2024
    “…<p>Aging population has led to an increased prevalence of chronic and degenerative pathologies. A manifestation of unhealthy aging is frailty, a geriatric syndrome that implies a non-specific state of greater vulnerability. …”
  15. 435
  16. 436

    Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

    Published 2022
    “…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”
  17. 437

    Insensitivity to the Spatial Repellent Action of Transfluthrin in <i>Aedes aegypti</i>: A Heritable Trait Associated with Decreased Insecticide Susceptibility by Joseph M. Wagman (725058)

    Published 2015
    “…Compared to the SR responder strain, the SR insensitive strain also demonstrated decreased susceptibility to transfluthrin toxicity in CDC bottle bioassays and a higher frequency of the V1016I<sup><i>kdr</i></sup> mutation.…”
  18. 438
  19. 439
  20. 440